Skip to content Skip to sidebar Skip to footer

Telix Pharmaceuticals (ASX:TLX) refinances with US$600m 2031 convert at 1.5% coupon

Raises US$600m in convertible debt, cuts refinancing risk ahead of Pixclara PDUFA Telix Pharmaceuticals (ASX:TLX) is sourcing US$600 million of convertible debt, replacing nearer-dated debt with a longer-dated instrument that…

ByCharlie Youlden

Apr 2026

Healthcare Stocks

Telix Pharmaceuticals (ASX:TLX) Regeneron $14b revenue partner, 49m shorts face pressure

$40m Regeneron cheque validates RLS as 49m shorts watch Telix Pharmaceuticals (ASX:TLX) is building momentum after the positive NDA update for Pixclara, its PET imaging agent for glioma, a form…

ByCharlie Youlden

Apr 2026

Healthcare Stocks

Telix Pharmaceuticals (ASX:TLX) Big Upside, but Only if the FDA Says Yes.

Telix Pharmaceuticals, The Clock Is Now Running For many investors following Telix Pharmaceuticals (ASX:TLX), the story has been the sharp fall in the share price after the FDA setback, with…

ByCharlie Youlden

Jan 2026

Healthcare Stocks

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

Telix Pharmaceuticals Shares Slide After Regulatory Setbacks Telix Pharmaceuticals (ASX: TLX) has had a brutal twelve months. Shares have fallen around 63% from their February 2025 all-time high of A$31.97…

ByUjjwal Maheshwari

Dec 2025

Healthcare Stocks Tech Stocks

Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial

TLX Delivers Clinical Progress It’s good to finally see some positive news from Telix Pharmaceuticals (ASX:TLX) after a relatively quiet period, especially following recent market nerves around the FDA slowdown…

ByCharlie Youlden

Apr 2025

Healthcare Stocks

Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!

What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful story? It would have been possible believe back in those…

ByNick Sundich

Nov 2024

General

4 of the best ASX IPOs in the last decade!

In this article, we recap the best ASX IPOs in the last decade. Investing in IPOs is a big risk because there is no guarantee things will go well. It is…

ByNick Sundich

Oct 2023

Healthcare Stocks

FDA approval: Here’s how ASX biotechs and medtechs obtain it

Last week one of our favourite companies Cyclopharm (ASX:CYC) obtained FDA approval, a goal it had been striving for years to obtain and one that wasn't reached without setbacks along…

ByNick Sundich

the Kick-ass Multipurpose WordPress Theme

Telix Pharmaceuticals (ASX:TLX) refinances with US$600m 2031 convert at 1.5% coupon

Telix Pharmaceuticals (ASX:TLX) Regeneron $14b revenue partner, 49m shorts face pressure

Telix Pharmaceuticals (ASX:TLX) Big Upside, but Only if the FDA Says Yes.

Is Telix Pharmaceuticals (ASX:TLX) a Buy After Crashing 63%? Here’s What Investors Should Know

Telix Pharmaceuticals (ASX:TLX) Back on Track, First Patient Dosed in Phase 3 PROSTACT Trial

Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!

4 of the best ASX IPOs in the last decade!

FDA approval: Here’s how ASX biotechs and medtechs obtain it

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here